TO THE EDITOR: In a recent letter to the Editor, van Steelandt et al.(I) reported that they
were able to detect somatostatin receptors in schwannomas using an indirect in vitro …

TO THE EDITOR: I read with interest the paper by Lebtahi et al.(1) describing incidental
visualization by Octreoscan of an accessory spleen but not of the tumor itself in a patient with …

The last 2 years have brought significant progress for the clinical use of somatostatin
receptor (SSR) targeted imaging and therapy in the United States. In 2016, the Food and …

TO THE EDITOR: Radiolabeled somatostatin agonists are valuable tools for imaging and
treating neuroendocrine tumors. Although somatostatin receptors are also expressed in …

Somatostatin receptors (SSRs) are expressed in a number of normal cells including the
pituitary, thyroid, spleen, kidney and peripheral nervous system. In addition, several tumours …

We report our experience with the 111In-pentetreotide scanning of 47 adult patients
presenting with neuroendocrine tumors (n= 38) or malignant pheochromocytomas or related …

Verification of the presence of somatostatin receptors on neuroendocrine tumour cells
opened up unique diagnostic and therapeutic possibilities. Long-acting somatostatin …

In vivo somatostatin receptor-mediated scintigraphy has proven to be a valuable method for
the visualisation of neuroendocrine tumours and their metastases. A new application is the …

We read with great interest the recent article by Hornick et al.(1) on the subcellular
distribution of 111 In-and 125 I-labeled somatostatin analogs. We applaud the authors for …

Background: Somatostatin receptors have been found on a variety of neuroendocrine
tumours, such as carcinoids and paragangliomas, as well as on most pancreatic endocrine …